{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"10"}],"title":"Subjects with FN"},{"measurements":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"29"}],"title":"Subject without FN"}],"denoms":[{"counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"39"}],"units":"Participants"}],"title":"Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"title":"Subjects with FN"},{"measurements":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"37"}],"title":"Subject without FN"}],"denoms":[{"counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"38"}],"units":"Participants"}],"title":"Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"title":"Subjects with FN"},{"measurements":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"37"}],"title":"Subject without FN"}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"37"}],"units":"Participants"}],"title":"Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"title":"Subjects with FN"},{"measurements":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"37"}],"title":"Subject without FN"}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"37"}],"units":"Participants"}],"title":"Cycle 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"11"}],"title":"Subjects with FN"},{"measurements":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"28"}],"title":"Subject without FN"}],"denoms":[{"counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"39"}],"units":"Participants"}],"title":"All cycles"}],"denoms":[{"counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"39"}],"units":"Participants"}],"description":"Febrile neutropenia is defined as a single oral temperature of ≥38.3°C (101°F) or a temperature of \\>38.0°C (100.4°F) sustained for \\>1 hour and ANC \\< 0.5 x 10\\^9/L","groups":[{"description":"F-627, 20 mg fixed dose pre-filled syringe, dosed Day 2 of each of 4 chemotherapy cycles.","id":"OG000","title":"F-627"},{"description":"Placebo, pre-filled syringe administered Day 2 of the first chemotherapy cycle; and F-627, 20 mg fixed dose pre-filled syringe administered Day 2 of each of the following 3 chemotherapy cycles.","id":"OG001","title":"Placebo"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"3 subjects terminated early.","reportingStatus":"POSTED","timeFrame":"4 chemotherapy cycles, about 12 weeks","title":"Number of Participants With Febrile Neutropenia (FN) for Each Chemotherapy Cycle and Over All Cycles","type":"SECONDARY","unitOfMeasure":"Participants"}